Loading…
S. 527119th CongressOn the floor calendarLatest action Apr 10, 2025Decoded by AI · checked against the record
Official title: Prescription Pricing for the People Act of 2025
Introduced:
Read the official bill on Congress.govThe plain-language version leads. The official text is always the reference.
S. 527 orders the FTC to study PBMs and sole-source drug makers and report findings to Congress, without creating new rules.
35-second read · 4 questions answered below
The bill directs the FTC to study pharmacy benefit managers (PBMs) and other drug supply chain middlemen, with a preliminary report due in 180 days and a full report within one year. It also requires a separate FTC report on complaints against "sole-source" drug manufacturers. The bill creates no new pricing rules and does not directly regulate PBMs or drug makers.
The FTC takes on new reporting duties. PBMs, drug manufacturers, pharmacies, insurers, and consumers could be affected later if Congress acts on the findings.
The reports could inform future legislation on drug pricing transparency and competition, but the bill itself changes no current practices or prices.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: it's on the Senate floor calendar. If the House changes it, it goes back to the Senate before reaching the President.
Latest action: — Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.